The vaccine, branded Arexvy, was approved by the U.S. Food and Drug Administration in June but the Centers for Disease Control and Prevention (CDC) did not recommend RSV shots for adults under 60 years.
Tag Archive for: GSK
GSK is seeking to relaunch Blenrep after its market withdrawal in 2022. The pharma is eyeing a second-line niche for the antibody-drug conjugate in the treatment of relapsed or refractory multiple myeloma.
The deal boosts GSK’s messenger RNA credentials and extending the German biotech company’s financial lifeline.
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.
A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.
After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.
GSK and other drugmakers asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
The drug, called depemokimab, showed “significant and meaningful reductions” in asthma attacks for patients with eosinophilic asthma, the company stated.
The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley’s plans to boost earnings at the drugmaker.
CEO Emma Walmsley’s strategy has focussed on vaccines, cancer and infectious diseases and a shift in the company’s HIV focus to long-acting treatment and prevention therapies. The strategy has paid off as GSK gears up for 12 launches from 2025.